资源描述：
《参麦注射液联合同步放化疗治疗中晚期食管癌的临床观察》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。
1、参麦注射液联合同步放化疗治疗中晚期食管癌的临床观察30湖南中医药大学JournalOfTCMUniv.ofHunan2011年8月第31卷第8期Aug.2011Vo1.31No.8参麦注射液联合同步放化疗治疗中晚期食管癌的临床观察濮娟(江苏省涟水县人民医院放疗科,江苏淮安223400)[摘要]目的评价参麦注射液联合同步放化疗治疗中晚期食管癌的近期疗效和放化疗不良反应方法将94例中晚期食道癌患者随机分为对照组和试验组,2组均采用同步放化疗:放疗总量为6O～66Gy(6～7周),且在放疗dI,d29予以
2、2次FP方案化疗.试验组在上述给药基肚上再静脉注射参麦注射液60ml,d…,d292.结果试验组的近期有效率为83.O%,对照组为72l3%,两组差异具有统计学意义(P<O.05).试验组的IlJ/JV级消化道毒性反应,白细胞毒性反应发生率与对照组比较,均明显减轻(P<O.05).结论参麦注射液能够有效提高中晚期食管癌同步放化疗的临床疗效.且能显着减少放化疗的不良反应.(关键词]参麦注射液;同步放化疗;中晚期食道癌;不良反应【中图分类号]R735.1【文献标识码)A【文章编号)doi:1
3、0.3969~.issn.1674—070X.2011.08.011.030.03AClinicalStudyonthecombinationofShenmaiInjectionandConcurrentChemoradiotherapyforAdvancedEsophagealJ—'arcinomaPUJuan(DepartmentofRadiation,People'HospitalofLianshuicounty,JiangsuProvince,Huaian,Jiangsu223400,Chi
4、na)(Abstract)ObjectiveToobservetheshort—termefficacyandadversereactionsofthecombinationofShenmaiInjectionandconcurrentchemoradiotherapyforadvancedesophagealcarcinoma.MethodsAtotalof94patientswithadvancedesophagealcarcinomawererandomlyassignedtoeithertr
5、ialgrouporcontrolgroup,with47patientseach.Bothgroupsreceivedthesameconcurrentradiochemotherapy,includingradiotherapyatadoseof60—66Gy(6-7weeks)plusFPchemotherapyondays1and29ofradiotherapy.Meanwhile,thetrialgroupreceivedadd-onShenmaiInjectionwithadoseof6
6、0mlperdayondayl?14andday29-42.ResultsTheshorttermefficacyofthetrialgroupwas83.O%,ascomparedwith72.3%ofthecontrolgroup,showingasignificantdifferencesbetweenthetwogroupsrP<0.05).MeanwhiletheincidenceofIll/IVgradegastrointestinaltoxicityandwhitebloodce
7、lltoxicityinthetrialgroupweresignificantlyreduced,andshowingasignificantdifferencescomparedwiththecontrolgroup(P<O.05).ConclusionShenmaiInjectioncanimprovetheshort—termclinicalefficacyofconcurrentchemoradiotherapyinadvancedesophagealcarcinoma,andcan
8、significantlyreducethetoxicityofradiotherapyandchemotherapy.(Keywords)ShenmaiInjection;Concurrentchemoradiotherapy;Advancedesophagealcarcinoma;Adversereactions食管癌是高度侵袭性的肿瘤,有早期扩散和转移的倾向,就诊时约50%的患者因转移而不能手术切除.对于失去手术机会或者拒绝手术的中晚期食管癌患者,同步放化疗则是
